Open tender · Germany · Pharmaceutical products
Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Nilotinib (L01EA03), ohne die Verabreichung dispergiert in Apfelmus (püriertem Apfel) im Rahmen eines sogenannten Open-House-Modells
In EnglishConclusion of non-exclusive rebate contracts pursuant to Sections 130a (8) / 130c (1) SGB V for pharmaceutical products containing the active ingredient nilotinib (L01EA03), excluding administration dispersed in applesauce (pureed apple), within the framework of a so-called open-house model
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse in Germany is inviting bids for “Conclusion of non-exclusive rebate contracts pursuant to Sections 130a (8) / 130c (1) SGB V for pharmaceutical products containing the active…”. Bids close on 30 November 2026, 23:59 CET. askTender lists every requirement to qualify and checks whether your company meets them.
The work
Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Nilotinib (L01EA03), ohne die Verabreichung dispergiert in Apfelmus (püriertem Apfel) im Rahmen eines sogenannten Open-House-Modells.
Key facts
- Procedure
- Contract notice
Before you bid, askTender
Everything else is in your askTender account
The requirements to qualify, the eligibility check and the bid documents for this tender are in your askTender account.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences